XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Income Statement Information (Tables)
 3 Months Ended
Mar. 29, 2025
Supplemental Income Statement Elements [Abstract]  
Schedule of Disaggregated Revenues
Revenues by type are as follows:
Three months ended
(In millions)March 29, 2025March 30, 2024
Revenues
Consumables
$4,354 $4,328 
Instruments
1,626 1,627 
Services
4,384 4,390 
Consolidated revenues$10,364 $10,345 
Revenues by geographic region based on customer location are as follows:
Three months ended
(In millions)March 29, 2025March 30, 2024
Revenues
North America
$5,513 $5,519 
Europe
2,624 2,619 
Asia-Pacific
1,891 1,861 
Other regions
337 346 
Consolidated revenues$10,364 $10,345 
Revenues by business are as follows:
Three months ended
(In millions)
March 29, 2025March 30, 2024
Revenues


Biosciences
$993 $1,059 
Genetic sciences
677 637 
BioProduction
671 590 
Life Sciences Solutions
2,341 2,285 
Chromatography and mass spectrometry
773 789 
Chemical analysis
286 320 
Electron microscopy
659 579 
Analytical Instruments
1,718 1,687 
Clinical diagnostics
263 263 
ImmunoDiagnostics
217 212 
Microbiology
152 153 
Transplant diagnostics
113 106 
Healthcare market channel
474 438 
Elimination of intrasegment revenues
(72)(63)
Specialty Diagnostics
1,148 1,109 
Laboratory products
582 624 
Research and safety market channel
1,727 1,711 
Pharma services
1,607 1,578 
Clinical research
1,939 2,033 
Elimination of intrasegment revenues
(214)(224)
Laboratory Products and Biopharma Services
5,640 5,723 
Elimination of intersegment revenues(482)(460)
Consolidated revenues$10,364 $10,345 
Schedule of Restructuring and Other Costs by Segment
Restructuring and other costs by segment are as follows:
Three months ended
(In millions)March 29, 2025
Life Sciences Solutions
$42 
Analytical Instruments
4 
Specialty Diagnostics
2 
Laboratory Products and Biopharma Services
45 
Corporate
5 
$98 
Schedule of Changes in the Company's Accrued Restructuring Balance
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.
(In millions)Total (a)
Balance at December 31, 2024$50 
Net restructuring charges incurred in 2025 (b)
43 
Payments
(34)
Currency translation
1 
Balance at March 29, 2025$59 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $55 million of net charges, principally $68 million of charges for impairment of long-lived assets in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
Schedule of Earnings Per Share
Three months ended
March 29,March 30,
(In millions except per share amounts)20252024
Net income attributable to Thermo Fisher Scientific Inc.$1,507 $1,328 
Basic weighted average shares378 382 
Plus effect of: stock options and restricted stock units1 2 
Diluted weighted average shares379 384 
Basic earnings per share$3.99 $3.47 
Diluted earnings per share$3.98 $3.46 
Antidilutive stock options excluded from diluted weighted average shares
3 2